Clinical trials bring life extending and curative new treatments to cancer patients. Clinical drug trials play a vital role in moving new treatments to patients who need them most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients.

There are currently over 90 Phase III drug trials and more than 400 Phase I/II trials in process for prostate cancer in North America and Europe. Those that are approved will join the five new drugs that have been approved for men with advanced metastatic disease since 2010 and further improve outcomes for patients:

Jevtana (cabazitaxel)

Provenge (sipuleucel-T)

Xgeva (denusomab)

Xofigo (radium 223 dichloride)

Xtandi (enzalutimide)

Zytiga (abiraterone)

The resources on this page can direct you to clinical trials that are currently open for enrollment in your local area, as well as across the country. If you are considering a clinical trial, speak to your doctor about the potential benefits of participating in a trial so you can make an informed decision that is best for you.


Frequently Asked Questions (FAQs)

To view our FAQs about Clinical Trials, please visit here.


 

Prostate Cancer Clinical Trials Consortium

The Prostate Cancer Clinical Trials Consortium (PCCTC) is a clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP), with its Coordinating Center headquartered at Memorial Sloan-Kettering Cancer Center.  The PCCTC is currently composed of 11 participating clinical research sites and 21 affiliated clinical research sites.

Visit the PCCTC site for trial information: www.pcctc.org


Open Trials

For a complete list of open trials in the United States, please visit:

 

 


 

 

ARAMIS

A clinical research study for patients with prostate cancer that has not spread beyond the prostate

Bayer HealthCare is seeking men who have prostate cancer to participate in a research study of an investigational drug. The purpose of the ARAMIS trial is to determine the safety and effectiveness of an investigational drug in delaying prostate cancer spreading from the prostate. This study is enrolling patients with prostate cancer that is at risk of progressing, but has not already spread to other areas of the body. Eligible patients must have rising prostate specific antigen (PSA) values without spread of their prostate cancer to other areas of the body.

If you are currently receiving hormone therapy, your treatment will continue and in addition you will receive either the investigational medication or placebo. Two out of every 3 patients will receive investigational medication and the assignment to the medication will be random.

To learn more about the ARAMIS trial and to find out if you may be eligible, please visit: http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php (Trial Number: 17712) orwww.clinicaltrials.gov (Study Identifier: NCT02200614)


 

 

The SPARTAN Study

A clinical research study for patients whose prostate cancer has not spread beyond the prostate is now enrolling

Aragon Pharmaceuticals is seeking men to participate in a clinical trial of an investigational drug for prostate cancer. The purpose of the SPARTAN study is to evaluate the safety and effectiveness of an investigational drug in delaying prostate cancer from spreading beyond the prostate. This study is enrolling patients with prostate cancer who, despite treatment, have rising blood prostate-specific antigen (PSA) levels. All participants will continue to receive their current treatment along with either the investigational medication or a placebo. The selections will be random, and the investigational medication will be given to 2 out of every 3 study participants.

To learn more about the SPARTAN Study and to find out if you may be eligible, please visit: SPARTAN Study or www.clinicaltrials.gov
Study Identifier: NCT01946204

Aragon Pharmaceuticals, Inc.
Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson and provides various services to its affiliate, Aragon Pharmaceuticals, Inc.

 

The TITAN Study

A clinical research study for men who have metastatic, hormone-sensitive prostate cancer is now enrolling. Janssen Research & Development is seeking men to participate in a clinical trial of an oral investigational drug for prostate cancer. This study is enrolling men who are either surgically castrated or taking Androgen Deprivation Therapy (ADT). The selections will be random, and the investigational medication will be given to 1 out of every 2 study participants.

To learn more about the TITAN Study and to find out if you may be eligible, please visit:http://www.titanprostatecancer.com/?p=2933PRCANC orwww.clinicaltrials.gov
Study Identifier: NCT02489318

Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

 

The ATLAS Study

A clinical research study is now enrolling for men who have high-risk, localized or locally advanced prostate cancer and are receiving radiation therapy. Janssen Research & Development is seeking men to participate in a clinical trial of an investigational drug for prostate cancer. The selections will be random, and the investigational medication will be given to 1 out of every 2 study participants.

To learn more about the ATLAS Study and to find out if you may be eligible, please visit:http://www.atlasprostatecancer.com/?p=3079PRCANC or www.clinicaltrials.gov
Study Identifier: NCT02531516

Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.


 

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

The study will consist of 2 parts: Part I (Dose Escalation) and Part II (Dose Expansion). In Part I, patients will participate in single, multiple, and long-term dosing periods using EPI-506 to determine safety, pharmacokinetics, the maximum tolerated dose, and preliminary indications of anti-tumor activity. Part I is an open-label, adaptive 3 + 3 design, dose-escalation study. Up to six dose levels of EPI-506 will be studied, beginning at 80 mg/day. Patients may be allowed to escalate sequentially to a higher dose cohort after twelve weeks of dosing.

In Part II, 3 patient populations; post-abiraterone metastatic castration-resistant prostate cancer (mCRPC) but enzalutamide-naïve, post-enzalutamide mCRPC but abiraterone-naïve, and post-abiraterone and enzalutamide mCRPC will be studied at the recommended Phase 2 dose (RP2D) determined in Part I over 12 weeks of daily dosing. Approximately 120 patients (40 in each cohort) will be enrolled.

To learn more about this study and to find out if you may be eligible, please visit:https://clinicaltrials.gov/ct2/show/NCT02606123?term=EPI-506&rank=1

 


Additional open trials can be found by going to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Literature:

Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials

Tomasz M. Beer, MD
Larry Axmaker, Ed.D.

Written from both a patient and clinician perspective by Larry Axmaker, Ed.D., and Tomasz M. Beer, MD, a PCF-funded researcher, this book is an insightful resource for anyone considering clinical trials in addition to standard cancer therapy. Order Here »

Terms to know from this article:

PSA

prostate-specific antigen (PSA): A substance produced by the prostate that may be found in an increased amount in the blood of men who have prostate cancer, benign prostatic hyperplasia, or infection or inflammation of the prostate.

Tumor

A mass of excess tissue that results from abnormal cell division. Tumors perform no useful body function. They may be benign (not cancerous) or malignant (cancerous).

Learn More